Reporting of MABp1 for the treatment of psoriasis

JAMA Dermatology

Volumn 151, Issue 10, 2015, Pages 1143-1144

  Mansouri, Bobbak ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DERMATOLOGICAL AGENT; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1ALPHA; MABP 1; PROTEIN INHIBITOR; SECUKINUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; MONOCLONAL ANTIBODY;

CLINICAL EFFECTIVENESS; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; TREATMENT OUTCOME; TREATMENT RESPONSE; METABOLISM;

ANTIBODIES, MONOCLONAL; HUMANS; INTERLEUKIN-1ALPHA; PSORIASIS;

EID: 84944345328     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.1684     Document Type: Letter

References (5)

1. Coleman KM, Gudjonsson JE, Stecher M. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1α, for the treatment of psoriasis. JAMA Dermatol. 2015;151(5):555-556.
2. Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239-241.
3. Viguier M, Guigue P, Pages C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153(1):66-67.
4. Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13(12):1715-1730.
5. Langley RG, Elewski BE, Lebwohl M, et al; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.